These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 16110075)
1. Need for differential discounting of costs and health effects in cost effectiveness analyses. Brouwer WB; Niessen LW; Postma MJ; Rutten FF BMJ; 2005 Aug; 331(7514):446-8. PubMed ID: 16110075 [TBL] [Abstract][Full Text] [Related]
2. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Claxton K; Sculpher M; Culyer A; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J Health Econ; 2006 Jan; 15(1):1-4. PubMed ID: 16365910 [TBL] [Abstract][Full Text] [Related]
3. Valuing prevention: discounting health benefits and costs in New Zealand. Milne R N Z Med J; 2005 May; 118(1214):U1443. PubMed ID: 15886738 [No Abstract] [Full Text] [Related]
4. Prevention, policy, and paradox: what is the value of future health? Ganiats TG Am J Prev Med; 1997; 13(1):12-7. PubMed ID: 9037337 [TBL] [Abstract][Full Text] [Related]
5. Health and the economy: a British view. Howe G Health Aff (Millwood); 1981; 1(1):30-8. PubMed ID: 10621742 [No Abstract] [Full Text] [Related]
6. Should NICE's threshold range for cost per QALY be raised? No. Raftery J BMJ; 2009 Jan; 338():b185. PubMed ID: 19171562 [No Abstract] [Full Text] [Related]
7. Should NICE's threshold range for cost per QALY be raised? Yes. Towse A BMJ; 2009 Jan; 338():b181. PubMed ID: 19171561 [No Abstract] [Full Text] [Related]
8. The cost-effectiveness of environmental approaches to disease prevention. Chokshi DA; Farley TA N Engl J Med; 2012 Jul; 367(4):295-7. PubMed ID: 22830461 [No Abstract] [Full Text] [Related]
9. Rescuing innovation. Hughes-Hallett T Health Serv J; 2012 May; 122(6304):20. PubMed ID: 22667166 [No Abstract] [Full Text] [Related]
10. The cost-effectiveness of public health interventions. Owen L; Morgan A; Fischer A; Ellis S; Hoy A; Kelly MP J Public Health (Oxf); 2012 Mar; 34(1):37-45. PubMed ID: 21933796 [TBL] [Abstract][Full Text] [Related]
11. Aging diseases--do they prevent preventive health care from saving costs? Gandjour A Health Econ; 2009 Mar; 18(3):355-62. PubMed ID: 18833543 [TBL] [Abstract][Full Text] [Related]
12. Unintended consequences of applying economic evaluation. Oliver A J Health Serv Res Policy; 2002 Jul; 7(3):129-30. PubMed ID: 12171741 [No Abstract] [Full Text] [Related]
13. Cost-effectiveness considerations at NICE. Rawlins M; Dillon A Lancet; 2008 Oct; 372(9646):1302. PubMed ID: 18929903 [No Abstract] [Full Text] [Related]
14. When Opportunity Knocks, What Does It Say? Phelps CE Value Health; 2019 Aug; 22(8):851-853. PubMed ID: 31426924 [No Abstract] [Full Text] [Related]
15. The methodologic partnership of effectiveness reviews and cost-effectiveness analysis. Russell LB Am J Prev Med; 2001 Apr; 20(3 Suppl):10-2. PubMed ID: 11306227 [No Abstract] [Full Text] [Related]
16. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention? Phillips KA; Hotlgrave DR Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338 [TBL] [Abstract][Full Text] [Related]
20. Richard Milne responds to PHARMAC on discounting future health benefits and costs. Milne R N Z Med J; 2005 Aug; 118(1220):U1620. PubMed ID: 16132078 [No Abstract] [Full Text] [Related] [Next] [New Search]